# Effect of Netazepide on Omeprazole-induced Changes in Chromogranin A and Gastrin

> **NCT02620696** · PHASE1 · COMPLETED · sponsor: **Trio Medicines Ltd.** · enrollment: 48 (actual)

## Conditions studied

- ECL-cell Hyperplasia
- Parietal-cell Hyperplasia
- Rebound Hyperacidity
- Dyspepsia

## Interventions

- **DRUG:** netazepide

## Key facts

- **NCT ID:** NCT02620696
- **Lead sponsor:** Trio Medicines Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2015-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02620696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02620696, "Effect of Netazepide on Omeprazole-induced Changes in Chromogranin A and Gastrin". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02620696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*